Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
Open accessThe DOI matches its Crossref record; 165 of the 166 references it cites were found in a registry or an index.
Abstract
Cetuximab and panitumumab, as the highly effective antibodies targeting epidermal growth factor receptor (EGFR), have clinical activity in the patients with metastatic colorectal cancer (mCRC). These agents have good curative efficacy, but drug resistance also exists at the same time. The effects of KRAS, NRAS, and BRAF mutations and HER2 amplification on the treatment of refractory mCRC have been elucidated and the corresponding countermeasures have been put forward. However, the changes in EGFR and its ligands, the mutations or amplifications of PIK3CA, PTEN, TP53, MET, HER3, IRS2, FGFR1, and MAP2K1, the overexpression of insulin growth factor-1, the low expression of Bcl-2-interacting mediator of cell death, mismatch repair-deficient, and epigenetic instability may also lead to drug resistance in mCRC. Although the emergence of drug resistance has genetic or epigenetic heterogeneity, most of these molecular changes relating to it are focused on the key signaling pathways, such as the RAS/RAF/mitogen-activated protein kinase or phosphatidylinositol 3-kinase/Akt/mammalian target of the rapamycin pathway. Accordingly, numerous efforts to target these signaling pathways and develop the novel therapeutic regimens have been carried out. Herein, we have reviewed the underlying mechanisms of the resistance to anti-EGFR therapy and the possible implications in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Elevated plasma levels of EGFR ligands such as epiregulin (EREG) and amphiregulin (AREG) may be indicative of resistance to anti-EGFR therapy [29].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [29]
In the citing paper
“Whereas PI3K inhibitors and mTOR inhibitors have been developed and approved for clinical trials in PIK3CA-mutated solid tumors [164].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [164]
In the citing paper
“There is increasing evidence that aberrant activation of this pathway is associated with anti-EGFR treatment resistance [164].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [164]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“8 million new CRC cases and 881,000 deaths were estimated to have occurred in 2018 and the incidence and mortality rank third and second, respectively [1].”
BackgroundBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“Among them, BRAF accounts for >90% of BRAF mutations, which refers to the T-to-A changing at nucleotide 1799 and a substitution of valine to glutamic acid [64].”
BackgroundComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Global patterns and trends in colorectal cancer incidence and mortality
Arnold, M., Sierra, M. S., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2017) · Gut · doi:10.1136/gutjnl-2015-310912 · Cited by 5,228 · cited 1×
“Fortunately, although the incidence and mortality of CRC in some underdeveloped areas are still increasing, they are declining in the whole world, especially in the developed countries [3].”
Backgroundras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions*
JONES, J. I., & CLEMMONS, D. R. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-3 · Cited by 4,710
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · cited 1×
“transcription 3 (STAT3) [124]; besides, HGFR can also be coupled with HER3 to form a heterodimer under certain conditions [125].”
BackgroundCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,662 · cited 1×
“Epigenetic instability includes aberrant DNA methylation, histone modification, chromosome remodeling, and noncoding RNA interference [154]; aberrant methylation phenotypes and microRNA (miRNA) interference are closely related to both the development and the drug resistance of CRC [155].”
BackgroundK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 1×
“In 2013, a paper showed that KRAS G12C could be targeted by a covalent compound that locks the mutant protein in its inactive GDPbound state, which is supported by the discovery that KRAS G12C retains the highest residual intrinsic GTPase activity [52].”
BackgroundThe Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 1×
“Although the use of cetuximab and panitumumab has greatly improved the overall survival (OS) and other clinical outcomes of mCRCs [4, 5], some patients cannot benefit from it.”
BackgroundIdentification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product
Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M.-L., Kmiecik, T. E., Vande Woude, G. F., & Aaronson, S. A. (1991) · Science · doi:10.1126/science.1846706 · Cited by 2,236
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229 · cited 1×
“[44] first reported that the mutations of KRAS can reduce the efficacy of anti-EGFR mAbs in 2006, emerging studies have confirmed that RAS mutations are the major causes of resistance to anti-EGFR therapy [5, 43, 45–50].”
BackgroundEGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058 · cited 1×
“After binding to its ligands through the extracellular binding region, the proteins in the signal-transduction region phosphorylate and this finally leads to the intracellular cascade reactions that mainly promote cell proliferation [10, 18, 19].”
BackgroundUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · cited 1×
“They are mainly used in the treatment of melanoma, but the efficacy of single-agent therapy for mCRCs remains unclear [68], which is mainly related to the fact that, after inhibiting the MAPK pathway using BRAF inhibitors, EGFR can be activated by feedback in mCRCs, whereas melanoma only expresses low-level EGFR [69,…”
BackgroundEGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004 · cited 2×
“PTEN plays a role as 3phosphatase that dephosphorylates PIP3 or PIP2, and therefore inhibits the activation of PI3K and blocks this pathway [18, 75, 76].”
BackgroundWeisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A., Kang, G. H., Widschwendter, M., Weener, D., Buchanan, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1834 · Cited by 1,990 · cited 1×
“Some analyses have shown that CIMP often accompanies BRAF mutations and relates to the low expression of MLH1, AREG, and EREG in CRCs, which may be a major mechanism by which patients are resistant to anti-EGFR mAbs [158, 159].”
BackgroundVan Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581 · cited 1×
“For example, in lung cancer, the EGFR gene copy number (GCN) or mutations (especially EGFR) has been confirmed to be related to the resistance of molecule-targeted drugs [20, 21]; in the latest molecular-detection guideline of lung cancer, the importance of both EGFR GCN and mutations detection before the targeted tre…”
BackgroundEncorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 1×
“At present, the abnormalities of the RAS family have been reported to be related to a variety of tumors, and the mutations of KRAS and NRAS closely relate to CRC among them, but the relationship between CRC and the abnormality of HRAS is rarely reported [36].”
BackgroundVan Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
Scatter factor is a fibroblast-derived modulator of epithelial cell mobility
Stoker, M., Gherardi, E., Perryman, M., & Gray, J. (1987) · Nature · doi:10.1038/327239a0 · Cited by 1,314 · cited 5×
“In recent years, the agents and relative clinical trials that deserve our special attention mainly include specific MET tyrosine kinase volitinib, conjugated drugs ABBV-399 and SHRA1403, and dual-action EGFR/HGFR mAbs Sym-015, JNJ- 61186372, LY3164530, and EMB01 (Table 2).”
BackgroundInfluentialHallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
MET signalling: principles and functions in development, organ regeneration and cancer
Trusolino, L., Bertotti, A., & Comoglio, P. M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3012 · Cited by 1,240 · cited 2×
“The binding of HGF and HGFR leads to efficient activation of downstream signaltransduction pathways that include MAPK cascades, PI3K/Akt axis, the nuclear factor-jB inhibitor-a (IjBa)–nuclear factor-jB (NF-jB) complex, and the signal transducer and activator of transcription 3 (STAT3) [124]; besides, HGFR can also be…”
BackgroundThe RAF proteins take centre stage
Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,228 · cited 1×
“signal transduction and regulates cell proliferation [62].”
Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125 · cited 1×
“As early as 2007, researchers had noticed that the expression levels of EREG and AREG are related to the efficacy of cetuximab in mCRCs [33].”
BackgroundStructural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118
Rajaram, S., Baylink, D. J., & Mohan, S. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0321 · Cited by 1,097
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,036 · cited 1×
“HER2 (ERBB2/neu) does not bind with EGF-like ligands, but it acts as the preferred heterodimer partner of the other three members of the ERBB family [91].”
BackgroundCorcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022 · cited 1×
“They are mainly used in the treatment of melanoma, but the efficacy of single-agent therapy for mCRCs remains unclear [68], which is mainly related to the fact that, after inhibiting the MAPK pathway using BRAF inhibitors, EGFR can be activated by feedback in mCRCs, whereas melanoma only expresses low-level EGFR [69,…”
BackgroundSartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016 · cited 3×
“The conjugated agents ado-trastuzumab-emtansine (T-DM1) and tratuzumabhyaluronidase-oysk were approved for markets by the USA, Europe, and China for the treatment of HER2-positive breast cancer in 2019, but they have been rarely tried for mCRC.”
BackgroundPeeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005
Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., Idziaszczyk, S., Harris, R., Fisher, D., Kenny, S. L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60613-2 · Cited by 960 · cited 1×
“Although the use of cetuximab and panitumumab has greatly improved the overall survival (OS) and other clinical outcomes of mCRCs [4, 5], some patients cannot benefit from it.”
BackgroundMoroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939
Ras in Cancer and Developmental Diseases
Fernandez-Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 897
Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers
Okugawa, Y., Grady, W. M., & Goel, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.011 · Cited by 782 · cited 2×
“Epigenetic instability includes aberrant DNA methylation, histone modification, chromosome remodeling, and noncoding RNA interference [154]; aberrant methylation phenotypes and microRNA (miRNA) interference are closely related to both the development and the drug resistance of CRC [155].”
BackgroundEGF receptor trafficking: consequences for signaling and cancer
Tomas, A., Futter, C. E., & Eden, E. R. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.11.002 · Cited by 779
Linardou, H., Dahabreh, I. J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Papadimitriou, C. A., & Murray, S. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70206-7 · Cited by 739 · cited 1×
“At the same time, in order to solve the problem of genes-detection sensitivity and specificity, not only should genes testing be performed only in the laboratories that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), but also the latest National Comprehensive Cancer Network (NCCN)…”
BackgroundSartore-Bianchi, A., Martini, M., Molinari, F., Veronese, S., Nichelatti, M., Artale, S., Di Nicolantonio, F., Saletti, P., De Dosso, S., Mazzucchelli, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2466 · Cited by 739
Epigenetics and colorectal cancer
Lao, V. V., & Grady, W. M. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.173 · Cited by 736 · cited 1×
“The data have shown that methylation events are more common than mutations in CRC patients [155, 156].”
BackgroundA quantitative protein interaction network for the ErbB receptors using protein microarrays
Jones, R. B., Gordus, A., Krall, J. A., & MacBeath, G. (2006) · Nature · doi:10.1038/nature04177 · Cited by 727 · cited 1×
“Meanwhile, HER2 can bind more phosphotyrosine-binding protein than the other receptors [93].”
BackgroundPhase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697 · cited 1×
“They are mainly used in the treatment of melanoma, but the efficacy of single-agent therapy for mCRCs remains unclear [68], which is mainly related to the fact that, after inhibiting the MAPK pathway using BRAF inhibitors, EGFR can be activated by feedback in mCRCs, whereas melanoma only expresses low-level EGFR [69,…”
BackgroundPTEN: Life as a Tumor Suppressor
Simpson, L., & Parsons, R. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5130 · Cited by 679 · cited 1×
“PTEN plays a role as 3phosphatase that dephosphorylates PIP3 or PIP2, and therefore inhibits the activation of PI3K and blocks this pathway [18, 75, 76].”
BackgroundActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.12.001 · Cited by 645 · cited 1×
“For example, in lung cancer, the EGFR gene copy number (GCN) or mutations (especially EGFR) has been confirmed to be related to the resistance of molecule-targeted drugs [20, 21]; in the latest molecular-detection guideline of lung cancer, the importance of both EGFR GCN and mutations detection before the targeted tre…”
BackgroundCombined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
Corcoran, R. B., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., Siena, S., Middleton, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1226 · Cited by 592
Chen, W. S., Lazar, C. S., Poenie, M., Tsien, R. Y., Gill, G. N., & Rosenfeld, M. G. (1987) · Nature · doi:10.1038/328820a0 · Cited by 592 · cited 6×
“In recent years, the agents and relative clinical trials that deserve our special attention mainly include specific MET tyrosine kinase volitinib, conjugated drugs ABBV-399 and SHRA1403, and dual-action EGFR/HGFR mAbs Sym-015, JNJ- 61186372, LY3164530, and EMB01 (Table 2).”
BackgroundInfluentialBokemeyer, C., Cutsem, E. V., Rougier, P., Ciardiello, F., Heeger, S., Schlichting, M., Celik, I., & Köhne, C.-H. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.057 · Cited by 585
Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30904-5 · Cited by 573 · cited 3×
“The conjugated agents ado-trastuzumab-emtansine (T-DM1) and tratuzumabhyaluronidase-oysk were approved for markets by the USA, Europe, and China for the treatment of HER2-positive breast cancer in 2019, but they have been rarely tried for mCRC.”
BackgroundInsulin-like growth factors and cancer
Fürstenberger, G., & Senn, H.-J. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00731-3 · Cited by 536 · cited 1×
“sis, apoptosis, and other life processes together [139, 140].”
BackgroundMetastatic Colorectal Cancer: Current State and Future Directions
Fakih, M. G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7633 · Cited by 527
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
Koopman, M., Kortman, G. A. M., Mekenkamp, L., Ligtenberg, M. J. L., Hoogerbrugge, N., Antonini, N. F., Punt, C. J. A., & van Krieken, J. H. J. M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604867 · Cited by 515 · cited 1×
“Previous studies have suggested that dMMR is associated with a good prognosis in early-stage disease and is rare in advanced patients, especially in sporadic CRC [152].”
BackgroundResistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0462 · Cited by 513 · cited 1×
“Although the incidence of innate MET amplification in CRC patients is only 2%– 4% [129, 130], as MET is similar to HER2, some CRCs harbor acquired MET amplification during the process of anti-EGFR ther-”
BackgroundPietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479 · cited 1×
“Some changes that have been rarely reported include NTRK gene fusion, IRS2 amplification or mutations, FGFR1 and MAP2K1 mutations, and the low expression of the Bcl-2interacting mediator of cell death (Bim) [28, 150, 151]; the occurrence of unknown mutations mostly relates to dMMR.”
BackgroundSelf-citationAll ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired
Baulida, J., Kraus, M. H., Alimandi, M., Fiore, P. P. D., & Carpenter, G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.9.5251 · Cited by 454 · cited 1×
“In addition, the internalization process of dimers-containing HER2 will be slower and the receptors will return to the cell surface more effectively to receive the second stimulation [94, 95].”
BackgroundAntibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines
Kurai, J., Chikumi, H., Hashimoto, K., Yamaguchi, K., Yamasaki, A., Sako, T., Touge, H., Makino, H., Takata, M., Miyata, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1726 · Cited by 435
Adaptive mutability of colorectal cancers in response to targeted therapies
Russo, M., Crisafulli, G., Sogari, A., Reilly, N. M., Arena, S., Lamba, S., Bartolini, A., Amodio, V., Magrì, A., Novara, L., et al. (2019) · Science · doi:10.1126/science.aav4474 · Cited by 433 · cited 1×
“At the same time, the study also pointed out that the resistance to anti-EGFR agents in cancer cells will change from temporary to irreversible as the agents last longer [153], which put forward a new thinking on the choice of the targeted agents and the design of the treatment regimens.”
BackgroundLu, Y., Zhao, X., Liu, Q., Li, C., Graves-Deal, R., Cao, Z., Singh, B., Franklin, J. L., Wang, J., Hu, H., et al. (2017) · Nature Medicine · doi:10.1038/nm.4424 · Cited by 425 · cited 1×
“MiRNA-199a5p and miRNA-375 target PHLPP1, which indirectly activates the PI3K/AKT pathway [162], whereas miRNA-100/miRNA-125/ miRNA-181a-5p regulates the Wnt/b-catenin-signaling pathway [163].”
BackgroundCremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5080 · Cited by 424
Lenferink, A. E. G. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3385 · Cited by 413 · cited 1×
“In addition, the internalization process of dimers-containing HER2 will be slower and the receptors will return to the cell surface more effectively to receive the second stimulation [94, 95].”
BackgroundTherkildsen, C., Bergmann, T. K., Henrichsen-Schnack, T., Ladelund, S., & Nilbert, M. (2014) · Acta Oncologica · doi:10.3109/0284186x.2014.895036 · Cited by 390 · cited 1×
“Although the differences in the clinical outcomes between patients with single exon 9 mutations of PIK3CA and patients with single exon 20 mutations of PIK3CA are not significant, when there are double mutations in patients, the clinical outcomes will be worse [85, 86].”
BackgroundJacobs, B., De Roock, W., Piessevaux, H., Van Oirbeek, R., Biesmans, B., De Schutter, J., Fieuws, S., Vandesompele, J., Peeters, M., Van Laethem, J.-L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3744 · Cited by 368 · cited 1×
“Subsequently, accumulating studies have confirmed this finding; they have found that the higher the expression levels of these ligands, the better the observed efficacy of anti-EGFR mAbs in mCRCs can be, but this correlation is not consistent in patients with KRAS mutations [34].”
ResultRimassa, L., Assenat, E., Peck-Radosavljevic, M., Pracht, M., Zagonel, V., Mathurin, P., Rota Caremoli, E., Porta, C., Daniele, B., Bolondi, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30146-3 · Cited by 351
Oncogenic ERBB3 mutations in human cancers.
Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.012 · Cited by 350 · cited 1×
“7%–11% of CRCs harbor HER3 mutations [100, 103] and 51%–70% of CRCs show the overexpression of HER3 protein, but the evaluated criteria of HER3 overexpression are different [104, 105].”
BackgroundCatenacci, D. V. T., Tebbutt, N. C., Davidenko, I., Murad, A. M., Al-Batran, S.-E., Ilson, D. H., Tjulandin, S., Gotovkin, E., Karaszewska, B., Bondarenko, I., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30566-1 · Cited by 348
Sartore-Bianchi, A., Moroni, M., Veronese, S., Carnaghi, C., Bajetta, E., Luppi, G., Sobrero, A., Barone, C., Cascinu, S., Colucci, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5956 · Cited by 333
Spigel, D. R., Edelman, M. J., O’Byrne, K., Paz-Ares, L., Mocci, S., Phan, S., Shames, D. S., Smith, D., Yu, W., Paton, V. E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.2160 · Cited by 333
Worthylake, R., Opresko, L. K., & Wiley, H. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8865 · Cited by 325 · cited 1×
“Heterodimers such as EGFR/HER2 have higher affinity and specificity for the ligands [92].”
BackgroundK-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study
Brink, M. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg009 · Cited by 315 · cited 1×
“Although studies have shown that the status of KRAS and NRAS is independent of the tumor staging [37, 43], since Lievre et al.”
BackgroundHER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Kavuri, S. M., Jain, N., Galimi, F., Cottino, F., Leto, S. M., Migliardi, G., Searleman, A. C., Shen, W., Monsey, J., Trusolino, L., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1211 · Cited by 302 · cited 1×
“cation needs more evidence to support it [108].”
BackgroundEmergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Arena, S., Bellosillo, B., Siravegna, G., Martínez, A., Cañadas, I., Lazzari, L., Ferruz, N., Russo, M., Misale, S., González, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2821 · Cited by 271
The current state of molecular testing in the treatment of patients with solid tumors, 2019
El‐Deiry, W. S., Goldberg, R. M., Lenz, H., Shields, A. F., Gibney, G. T., Tan, A. R., Brown, J., Eisenberg, B., Heath, E. I., Phuphanich, S., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21560 · Cited by 264
The Genetic/Non-genetic Duality of Drug ‘Resistance’ in Cancer
Salgia, R., & Kulkarni, P. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.01.001 · Cited by 264 · cited 1×
“Although the study of miRNA interference with respect to resistance to anti-EGFR mAbs started relatively late, its role cannot be ignored due to the reversibility and activity of epigenetics that are similar to the interval drug resistance of mCRCs in clinic [161].”
BackgroundPrognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
Liao, X., Morikawa, T., Lochhead, P., Imamura, Y., Kuchiba, A., Yamauchi, M., Nosho, K., Qian, Z. R., Nishihara, R., Meyerhardt, J. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2410 · Cited by 258
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
Siena, S., Sartore-Bianchi, A., Marsoni, S., Hurwitz, H. I., McCall, S. J., Penault-Llorca, F., Srock, S., Bardelli, A., & Trusolino, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy100 · Cited by 244
van Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0795 · Cited by 232
Van Cutsem, E., Huijberts, S., Grothey, A., Yaeger, R., Cuyle, P.-J., Elez, E., Fakih, M., Montagut, C., Peeters, M., Yoshino, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02459 · Cited by 224
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Van Emburgh, B. O., Arena, S., Siravegna, G., Lazzari, L., Crisafulli, G., Corti, G., Mussolin, B., Baldi, F., Buscarino, M., Bartolini, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13665 · Cited by 214
Gjertsen, M. K., Breivik, J., Saeterdal, I., Thorsby, E., Gaudernack, G., Bakka, A., Søreide, O., & Solheim, B. G. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92408-6 · Cited by 213
PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K
Malek, M., Kielkowska, A., Chessa, T., Anderson, K. E., Barneda, D., Pir, P., Nakanishi, H., Eguchi, S., Koizumi, A., Sasaki, J., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.024 · Cited by 190 · cited 1×
“PTEN plays a role as 3phosphatase that dephosphorylates PIP3 or PIP2, and therefore inhibits the activation of PI3K and blocks this pathway [18, 75, 76].”
BackgroundPietrantonio, F., Vernieri, C., Siravegna, G., Mennitto, A., Berenato, R., Perrone, F., Gloghini, A., Tamborini, E., Lonardi, S., Morano, F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1863 · Cited by 182
Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0526 · Cited by 181
Mohan, S., Heitzer, E., Ulz, P., Lafer, I., Lax, S., Auer, M., Pichler, M., Gerger, A., Eisner, F., Hoefler, G., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004271 · Cited by 177 · cited 1×
“Meanwhile, 2% of patients harbor acquired mutations or amplification of HER2 gene after receiving anti-EGFR therapy, and their primary tumors mostly focus in the left colon and rectum and are RAS WT [101, 102].”
BackgroundHGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation
Liska, D., Chen, C.-T., Bachleitner-Hofmann, T., Christensen, J. G., & Weiser, M. R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0568 · Cited by 176
Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147
Gonsalves, W. I., Mahoney, M. R., Sargent, D. J., Nelson, G. D., Alberts, S. R., Sinicrope, F. A., Goldberg, R. M., Limburg, P. J., Thibodeau, S. N., Grothey, A., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju106 · Cited by 170 · cited 1×
“mentioned above, this type of patient situation is often accompanied by dMMR/MSI-H, so that anti-programmed death1 (PD1)/anti-programmed death ligand 1 (PD-L1) and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) immunotherapy may also have an ideal therapeutic effect [63, 74].”
BackgroundCarbone, D. P., Ciernik, I. F., Kelley, M. J., Smith, M. C., Nadaf, S., Kavanaugh, D., Maher, V. E., Stipanov, M., Contois, D., Johnson, B. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.158 · Cited by 169
Schirripa, M., Cremolini, C., Loupakis, F., Morvillo, M., Bergamo, F., Zoratto, F., Salvatore, L., Antoniotti, C., Marmorino, F., Sensi, E., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.28955 · Cited by 166 · cited 1×
“Although studies have shown that the status of KRAS and NRAS is independent of the tumor staging [37, 43], since Lievre et al.”
BackgroundMartin, V, Landi, L., Molinari, F., Fountzilas, G., Geva, R., Riva, A., Saletti, P., De Dosso, S., Spitale, A., Tejpar, S., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.4 · Cited by 156
Petrelli, F., Cabiddu, M., Borgonovo, K., & Barni, S. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr592 · Cited by 147
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.
Luraghi, P., Reato, G., Cipriano, E., Sassi, F., Orzan, F., Bigatto, V., De Bacco, F., Menietti, E., Han, M., Rideout, W. M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2340-t · Cited by 146
Reidy, D. L., Vakiani, E., Fakih, M. G., Saif, M. W., Hecht, J. R., Goodman-Davis, N., Hollywood, E., Shia, J., Schwartz, J., Chandrawansa, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.4154 · Cited by 138
Clancy, C., Burke, J. P., Kalady, M. F., & Coffey, J. C. (2013) · Colorectal Disease · doi:10.1111/codi.12427 · Cited by 133 · cited 1×
“mentioned above, this type of patient situation is often accompanied by dMMR/MSI-H, so that anti-programmed death1 (PD1)/anti-programmed death ligand 1 (PD-L1) and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) immunotherapy may also have an ideal therapeutic effect [63, 74].”
BackgroundVan Cutsem, E., Tejpar, S., Vanbeckevoort, D., Peeters, M., Humblet, Y., Gelderblom, H., Vermorken, J. B., Viret, F., Glimelius, B., Gallerani, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9243 · Cited by 132
Petrelli, F., Borgonovo, K., & Barni, S. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0257-x · Cited by 132
Toubaji, A., Achtar, M. S., Provenzano, M., Herrin, V. E., Behrens, R. J., Hamilton, M., Bernstein, S. A., Venzon, D. J., Gause, B. L., Marincola, F. M., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0477-6 · Cited by 129
Day, F. L., Jorissen, R. N., Lipton, L., Mouradov, D., Sakthianandeswaren, A., Christie, M., Li, S., Tsui, C., Tie, J., Desai, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3614 · Cited by 124 · cited 3×
“Such patients commonly have highgrade cancers at diagnosis and a higher number of cancerinvolved lymph nodes; they are more likely to be microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) and to progress rapidly [63].”
BackgroundInfluentialZanella, E. R., Galimi, F., Sassi, F., Migliardi, G., Cottino, F., Leto, S. M., Lupo, B., Erriquez, J., Isella, C., Comoglio, P. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010445 · Cited by 117
Seligmann, J. F., Elliott, F., Richman, S. D., Jacobs, B., Hemmings, G., Brown, S., Barrett, J. H., Tejpar, S., Quirke, P., & Seymour, M. T. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.6065 · Cited by 113
Van Cutsem, E., Eng, C., Nowara, E., Świeboda-Sadlej, A., Tebbutt, N. C., Mitchell, E., Davidenko, I., Stephenson, J., Elez, E., Prenen, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2752 · Cited by 110
Hecht, J. R., Mitchell, E., Neubauer, M. A., Burris, H. A., Swanson, P., Lopez, T., Buchanan, G., Reiner, M., Gansert, J., & Berlin, J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2017 · Cited by 110
Puzanov, I. J., Lindsay, C. R., Goff, L. W., Sosman, J. A., Gilbert, J., Berlin, J. D., Poondru, S., Simantov, R., Gedrich, R., Stephens, A. W., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0303 · Cited by 104 · cited 1×
“tumor activity in vivo [148]; unfortunately, before reaching the”
BackgroundPietrantonio, F., Oddo, D., Gloghini, A., Valtorta, E., Berenato, R., Barault, L., Caporale, M., Busico, A., Morano, F., Gualeni, A. V., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0297 · Cited by 103
Shen, Y., Wang, J., Han, X., Yang, H., Wang, S., Lin, D., & Shi, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081628 · Cited by 100
Lee, M. S., McGuffey, E. J., Morris, J. S., Manyam, G., Baladandayuthapani, V., Wei, W., Morris, V. K., Overman, M. J., Maru, D. M., Jiang, Z.-Q., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.87 · Cited by 98 · cited 1×
“Some analyses have shown that CIMP often accompanies BRAF mutations and relates to the low expression of MLH1, AREG, and EREG in CRCs, which may be a major mechanism by which patients are resistant to anti-EGFR mAbs [158, 159].”
BackgroundVitiello, P. P., Cardone, C., Martini, G., Ciardiello, D., Belli, V., Matrone, N., Barra, G., Napolitano, S., Della Corte, C., Turano, M., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1035-0 · Cited by 96
Sclafani, F., Kim, T. Y., Cunningham, D., Kim, T. W., Tabernero, J., Schmoll, H. J., Roh, J. K., Kim, S. Y., Park, Y. S., Guren, T. K., et al. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv258 · Cited by 92
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
Koganemaru, S., Kuboki, Y., Koga, Y., Kojima, T., Yamauchi, M., Maeda, N., Kagari, T., Hirotani, K., Yasunaga, M., Matsumura, Y., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0452 · Cited by 90
Stintzing, S., Kapaun, C., Laubender, R. P., Jung, A., Neumann, J. H. L., Modest, D. P., Giessen, C. A., Moosmann, N., Wollenberg, A., Kirchner, T., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27654 · Cited by 90
Sukawa, Y. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i45.6577 · Cited by 86
Oden-Gangloff, A., Di Fiore, F., Bibeau, F., Lamy, A., Bougeard, G., Charbonnier, F., Blanchard, F., Tougeron, D., Ychou, M., Boissière, F., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605008 · Cited by 84
Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia
Black, L. E., Longo, J. F., & Carroll, S. L. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.06.008 · Cited by 82 · cited 1×
“While the kinase activity of HER3 (ERBB3) is defective, it works by forming heterodimeric complexes with other receptors that are capable of generating potent cellular signals and then recruiting PI3K to six distinct sites in heterodimeric complexes, thus strongly activating PI3K in a RASindependent manner [96].”
BackgroundHu, Y. P., Patil, S. B., Panasiewicz, M., Li, W., Hauser, J., Humphrey, L. E., & Brattain, M. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0280 · Cited by 75 · cited 1×
“sis, apoptosis, and other life processes together [139, 140].”
BackgroundMiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1
Müssnich, P., Rosa, R., Bianco, R., Fusco, A., & D’Angelo, D. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1057569 · Cited by 75 · cited 1×
“MiRNA-199a5p and miRNA-375 target PHLPP1, which indirectly activates the PI3K/AKT pathway [162], whereas miRNA-100/miRNA-125/ miRNA-181a-5p regulates the Wnt/b-catenin-signaling pathway [163].”
BackgroundScartozzi, M., Mandolesi, A., Giampieri, R., Pierantoni, C., Loupakis, F., Zaniboni, A., Galizia, E., Giustini, L., Silva, R. R., Bisonni, R., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25193 · Cited by 74 · cited 1×
“mAbs in mCRCs [104, 143], whereas patients with IGF2 overex-”
BackgroundMeulendijks, D., Jacob, W., Martinez-Garcia, M., Taus, A., Lolkema, M. P., Voest, E. E., Langenberg, M. H. G., Fleitas Kanonnikoff, T., Cervantes, A., De Jonge, M. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1683 · Cited by 73
Eng, C., Bessudo, A., Hart, L. L., Severtsev, A., Gladkov, O., Müller, L., Kopp, M. V., Vladimirov, V., Langdon, R., Kotiv, B., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30049 · Cited by 72
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
Loree, J. M., Bailey, A. M., Johnson, A. M., Yu, Y., Wu, W., Bristow, C. A., Davis, J. S., Shaw, K. R., Broaddus, R., Banks, K. C., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy067 · Cited by 68 · cited 1×
“7%–11% of CRCs harbor HER3 mutations [100, 103] and 51%–70% of CRCs show the overexpression of HER3 protein, but the evaluated criteria of HER3 overexpression are different [104, 105].”
BackgroundIgarashi, H., Kurihara, H., Mitsuhashi, K., Ito, M., Okuda, H., Kanno, S., Naito, T., Yoshii, S., Takahashi, H., Kusumi, T., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4264-7 · Cited by 67
Scartozzi, M., Mandolesi, A., Giampieri, R., Bittoni, A., Pierantoni, C., Zaniboni, A., Galizia, E., Giustini, L., Silva, R. R., Bisonni, R., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0119 · Cited by 63
Hill, A. G., Findlay, M. P. N., Burge, M., Jackson, C., Alfonso, P., Samuel, L. M., Ganju, V., Karthaus, M., Amatu, A., Jeffery, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0646 · Cited by 63
Juric, D., Dienstmann, R., Cervantes, A., Hidalgo, M., Messersmith, W., Blumenschein, G. R., Tabernero, J., Roda, D., Calles, A., Jimeno, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2412 · Cited by 59
Segelov, E., Thavaneswaran, S., Waring, P. M., Desai, J., Robledo, K. P., Gebski, V. J., Elez, E., Nott, L. M., Karapetis, C. S., Lunke, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.6843 · Cited by 59
Trametinib in the treatment of multiple malignancies harboring MEK1 mutations
Lian, T., Li, C., & Wang, H. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101907 · Cited by 58 · cited 1×
“Some changes that have been rarely reported include NTRK gene fusion, IRS2 amplification or mutations, FGFR1 and MAP2K1 mutations, and the low expression of the Bcl-2interacting mediator of cell death (Bim) [28, 150, 151]; the occurrence of unknown mutations mostly relates to dMMR.”
BackgroundLin, H.-C., Lin, M.-H., Liao, J., Wu, T., Lee, T., Mi, F., Wu, C., Chen, K., Cheng, C., & Lin, C. (2016) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b04101 · Cited by 57 · cited 2×
“Preclinical studies have proved that antroquinol has a curative effect on RASmutant CRC [56, 57].”
BackgroundMarzi, L., Combes, E., Vié, N., Ayrolles-Torro, A., Tosi, D., Desigaud, D., Perez-Gracia, E., Larbouret, C., Montagut, C., Iglesias, M., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.313 · Cited by 53 · cited 1×
“Some changes that have been rarely reported include NTRK gene fusion, IRS2 amplification or mutations, FGFR1 and MAP2K1 mutations, and the low expression of the Bcl-2interacting mediator of cell death (Bim) [28, 150, 151]; the occurrence of unknown mutations mostly relates to dMMR.”
BackgroundLédel, F., Hallström, M., Ragnhammar, P., Öhrling, K., & Edler, D. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.008 · Cited by 52 · cited 1×
“7%–11% of CRCs harbor HER3 mutations [100, 103] and 51%–70% of CRCs show the overexpression of HER3 protein, but the evaluated criteria of HER3 overexpression are different [104, 105].”
BackgroundHER2-targeted therapy: an emerging strategy in advanced colorectal cancer
Salvia, A. L., López-Gómez, V., & García‐Carbonero, R. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1555583 · Cited by 49 · cited 1×
“Meanwhile, 2% of patients harbor acquired mutations or amplification of HER2 gene after receiving anti-EGFR therapy, and their primary tumors mostly focus in the left colon and rectum and are RAS WT [101, 102].”
BackgroundTargeting the epidermal growth factor receptor in metastatic colorectal cancer
Ng, K., & Zhu, A. X. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.09.006 · Cited by 48 · cited 1×
“In addition, 20% of new cases are diagnosed as metastatic colorectal cancer (mCRC) at the time of initial visiting [2].”
BackgroundBendell, J. C., Jones, S. F., Hart, L. L., Spigel, D. R., Lane, C. M., Earwood, C., Infante, J. R., Barton, J. H., & Burris, H. A. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0177-3 · Cited by 47 · cited 1×
“being used to treat refractory CRC [149].”
MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers
Angius, A., Pira, G., Scanu, A. M., Uva, P., Sotgiu, G., Saderi, L., Manca, A., Serra, C., Uleri, E., Piu, C., et al. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.35269 · Cited by 47
Bonomi, P., Gandara, D. R., Hirsch, F. R., Kerr, K. M., Obasaju, C. K., Paz-Ares, L. G., Bellomo, C., Bradley, J. D., Bunn, P. A., Culligan, M. J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy196 · Cited by 46 · cited 1×
“For example, in lung cancer, the EGFR gene copy number (GCN) or mutations (especially EGFR) has been confirmed to be related to the resistance of molecule-targeted drugs [20, 21]; in the latest molecular-detection guideline of lung cancer, the importance of both EGFR GCN and mutations detection before the targeted tre…”
BackgroundSignificance of mTOR Signaling and Its Inhibitor Against Cancer Stem-Like Cells in Colorectal Cancer
Cai, Z., Ke, J., He, X., Yuan, R., Chen, Y., Wu, X., Wang, L., Wang, J., Lan, P., & Wu, X. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3146-8 · Cited by 45 · cited 1×
“At present, mTOR inhibitors such as everolimus are mainly used in the targeted therapy of advanced renal-cell carcinoma; they have not been recommended for the treatment of mCRC [88, 89].”
BackgroundScartozzi, M., Giampieri, R., Maccaroni, E., Mandolesi, A., Giustini, L., Silva, R., Zaniboni, A., Biscotti, T., Biagetti, S., Galizia, E., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr558 · Cited by 43
Wolpin, B. M., Ng, K., Zhu, A. X., Abrams, T., Enzinger, P. C., McCleary, N. J., Schrag, D., Kwak, E. L., Allen, J. N., Bhargava, P., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0378 · Cited by 43 · cited 1×
“At present, mTOR inhibitors such as everolimus are mainly used in the targeted therapy of advanced renal-cell carcinoma; they have not been recommended for the treatment of mCRC [88, 89].”
BackgroundHo, C., Wang, J.-L., Lee, C.-C., Cheng, H.-Y., Wen, W., Cheng, H., & Chen, M. C.-M. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.09.008 · Cited by 37 · cited 2×
“Preclinical studies have proved that antroquinol has a curative effect on RASmutant CRC [56, 57].”
BackgroundRazis, E. D., Pentheroudakis, G. E., Rigakos, G., Bobos, M., Kouvatseas, G., Tzaida, O., Makatsoris, T., Papakostas, P., Bai, M. C., GOUSSIA, A. C., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1626-2 · Cited by 37
Ciardiello, F., & Normanno, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0261 · Cited by 36
Ouchi, K., Takahashi, S. I., Yamada, Y., Tsuji, S., Tatsuno, K., Takahashi, H., Takahashi, N., Takahashi, M., Shimodaira, H., Aburatani, H., et al. (2015) · Cancer Science · doi:10.1111/cas.12827 · Cited by 36 · cited 1×
“The wholegenome hypermethylation status of patients is significantly associated with the poor efficacy of anti-EGFR therapy, but many related mechanisms remain unclear [157].”
BackgroundBendell, J. C., Ervin, T. J., Gallinson, D. H., Singh, J., Wallace, J. A., Saleh, M. N., Vallone, M. K., Phan, S., & Hack, S. P. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.04.001 · Cited by 34
Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer
Schirripa, M., Loupakis, F., Lonardi, S., Cremolini, C., Bergamo, F., Zagonel, V., & Falcone, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv385 · Cited by 32
Bartolomeo, M. D., Pietrantonio, F., Perrone, F., Dotti, K. F., Lampis, A., Bertan, C. M., Beretta, E., Rimassa, L., Carbone, C., Biondani, P., et al. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0283-8 · Cited by 32
Lieu, C. H., Hidalgo, M. M., Berlin, J. D., Ko, A. H., Cervantes, A. M. R., LoRusso, P. M., Gerber, D. E., Eder, J. P., Eckhardt, S. G., Kapp, A. V., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0175 · Cited by 29
Llovet, P., Sastre, J., Sanz‐Ortega, J., Bando, I., Ferrer, M., Alfonso, P. G., Donnay, O., Carrato, A., Jiménez, A., Aranda, E., et al. (2015) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-015-0165-0 · Cited by 29
Wu, S., Ma, C.-C., & Li, W. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0380-3 · Cited by 29 · cited 1×
“Since 2011, emerging studies have reported that the resistance to anti-EGFR mAbs is related to the primary or acquired amplification and mutations of HER2 [106– 110], but the evidence does not support a prognostic role for HER2 overexpression [111].”
BackgroundModjtahedi (1992) · International Journal of Oncology · doi:10.3892/ijo_00000100 · Cited by 29
MET amplification, expression, and exon 14 mutations in colorectal adenocarcinoma
Zhang, M., Li, G., Sun, X., Ni, S., Tan, C., Xu, M., Huang, D., Ren, F., Li, D., Wei, P., et al. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.03.024 · Cited by 28 · cited 1×
“Although the incidence of innate MET amplification in CRC patients is only 2%– 4% [129, 130], as MET is similar to HER2, some CRCs harbor acquired MET amplification during the process of anti-EGFR ther-”
BackgroundSeligmann, J. F., Hatch, A. J., Richman, S. D., Elliott, F., Jacobs, B., Brown, S., Hurwitz, H., Barrett, J. H., Quirke, P., Nixon, A. B., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3168 · Cited by 25
Hickish, T., Cassidy, J., PROPPER, D. J., Chau, I., Falk, S. J., Ford, H. E. R., Iveson, T. J., Braun, M., Potter, V. A., Macpherson, I. R., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.08.008 · Cited by 25
Huemer, F., Thaler, J., Piringer, G., Hackl, H., Pleyer, L., Hufnagl, C., Weiß, L., & Greil, R. (2018) · BMC Cancer · doi:10.1186/s12885-017-3955-4 · Cited by 23
Zhang, D., Ye, J., Xu, T., & Xiong, B. (2013) · Journal of Chemotherapy · doi:10.1179/1973947813y.0000000070 · Cited by 20
Self-citationLièvre, A., Ouine, B., Canet, J., Cartier, A., Amar, Y., Cacheux, W., Mariani, O., Guimbaud, R., Selves, J., Lecomte, T., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.353 · Cited by 18
Cited by
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
The Role of EREG/EGFR Pathway in Tumor Progression
Cheng, W.-L., Feng, P.-H., Lee, K.-Y., Chen, K.-Y., Sun, W.-L., Van Hiep, N., Luo, C.-S., & Wu, S.-M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312828 · Cited by 239
“Although patients with metastatic colorectal cancer (mCRC) exhibited a high efficacy to anti-EGFR antibodies such as cetuximab or panitumumab, drug resistance was also observed in cancer cells [90,91].”
BackgroundThe path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 180
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and Challenges
Janani, B., Vijayakumar, M., Priya, K., Kim, J. H., Prabakaran, D. S., Shahid, M., Al-Ghamdi, S. H., Alsaidan, M. S., Bahakim, N. O., Abdelzaher, M. H., et al. (2022) · Vaccines · doi:10.3390/vaccines10040499 · Cited by 119
“EGF, transforming growth factor (TGF-), β-cellulin, epiregulin (EREG), epigen (EPGN), amphiregulin (AREG), and heparin-binding EGF are the most common EGFR ligands[24].”
Background
Metadata
- Authors
- Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N.
- Affiliations
- Department of Gastrointestinal Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, P. R. China
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Venue
- Gastroenterology Report
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-06-01
- Volume
- 8
- Issue
- 3
- Pages
- 179-191
- ISSN
- 2052-0034 (ISSN-L)
- PMC
- PMC7333932
- OpenAlex
- W3037750477
- Cited by
- 119
- References
- 166
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 23 · 2023: 17 · 2022: 23 · 2021: 17 · 2020: 1
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Gastroenterology report (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81871994, 81701834)
- Guangdong Natural Science Foundation (2019B151502063)
- Guangdong Science and Technology Planning Program (20190202018)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- anti-EGFR therapy, metastatic colorectal cancer, drug resistance, cetuximab, panitumumab, EGFR mutation, KRAS, NRAS, BRAF, HER2 amplification, PIK3CA, PTEN, TP53, MET, HER3, insulin receptor substrate 2, FGFR1, MEK1, insulin-like growth factor I, mismatch repair deficiency, epigenetic instability, Ras/Raf/MEK signaling, PI3K/AKT/mTOR pathway, combination therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.